Duopharma Biotech Bhd

Duopharma Biotech Bhd EBIT

The EBIT of Duopharma Biotech Bhd (DPHARMA.KL) as of Nov 21, 2026 is 100.65 M MYR. In the previous year, EBIT was 78.71 M MYR — a change of 27.87% (higher).

EBIT

100.65 MMYR

YoY

27.87%

Last updated:

In 2024, Duopharma Biotech Bhd's EBIT was 100.65 M MYR, a 27.87% increase from the 78.71 M MYR EBIT recorded in the previous year.

The Duopharma Biotech Bhd EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2020
81.86 M MYR
Jan 1, 2021
88.76 M MYR
Jan 1, 2022
92.91 M MYR
Jan 1, 2023
78.71 M MYR
Jan 1, 2024
100.65 M MYR
Jan 1, 2025 (e)
115.54 M MYR
Jan 1, 2026 (e)
116.36 M MYR
Jan 1, 2027 (e)
156.20 M MYR
The Duopharma Biotech Bhd EBIT history
YEAREBITYoY
est156.20 MMYR+34.24%
est116.36 MMYR+0.71%
est115.54 MMYR+14.79%
100.65 MMYR+27.87%
78.71 MMYR-15.28%
92.91 MMYR+4.68%
88.76 MMYR+8.43%
81.86 MMYR+5.99%
77.23 MMYR+18.30%
65.28 MMYR+20.18%
54.32 MMYR+65.64%
32.80 MMYR-34.65%
50.19 MMYR+7.29%
46.77 MMYR+16.35%
40.20 MMYR+12.92%
35.60 MMYR+2.89%
34.60 MMYR-1.14%
35.00 MMYR-7.41%
37.80 MMYR+8.31%
34.90 MMYR-14.88%
41.00 MMYR+12.02%
36.60 MMYR+12.96%
32.40 MMYR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Duopharma Biotech Bhd Revenue

Duopharma Biotech Bhd Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
569.90 M MYR
81.86 M MYR
58.61 M MYR
Jan 1, 2021
639.18 M MYR
88.76 M MYR
65.68 M MYR
Jan 1, 2022
696.72 M MYR
92.91 M MYR
70.11 M MYR
Jan 1, 2023
704.73 M MYR
78.71 M MYR
52.65 M MYR
Jan 1, 2024
813.70 M MYR
100.65 M MYR
62.65 M MYR
Jan 1, 2025 (e)
945.66 M MYR
115.54 M MYR
95.37 M MYR
Jan 1, 2026 (e)
1.02 B MYR
116.36 M MYR
103.61 M MYR
Jan 1, 2027 (e)
1.04 B MYR
156.20 M MYR
110.14 M MYR

Duopharma Biotech Bhd Margins

Duopharma Biotech Bhd stock margins

The Duopharma Biotech Bhd margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Duopharma Biotech Bhd. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Duopharma Biotech Bhd.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
40.92 %
14.36 %
10.28 %
Jan 1, 2021
39.74 %
13.89 %
10.28 %
Jan 1, 2022
40.16 %
13.34 %
10.06 %
Jan 1, 2023
38.08 %
11.17 %
7.47 %
Jan 1, 2024
37.06 %
12.37 %
7.70 %
Jan 1, 2025 (e)
37.06 %
12.22 %
10.09 %
Jan 1, 2026 (e)
37.06 %
11.45 %
10.20 %
Jan 1, 2027 (e)
37.06 %
15.03 %
10.60 %

Duopharma Biotech Bhd Stock analysis

What does Duopharma Biotech Bhd do? Duopharma Biotech Bhd generates revenue through its three business segments: Consumer Healthcare (CHC), Ethical Classic Business (ECB), and Ethical Specialty Business (ESB). The CHC segment sells over-the-counter products like vitamins, supplements, analgesics, eyecare, and antacids under brands such as Flavettes, CHAMPS, Uphamol, and Eye Glo to domestic, regional, and international markets. The ECB segment produces over 300 generic drugs including Crystorvas, Prelica, and Omesec, targeting healthcare providers and pharmacies. The ESB segment focuses on specialized drugs, medical devices, and consumables, while also commercializing biosimilars like ERYSAA, Basalog One, and Zuhera through international partnerships. The company's products are distributed across multiple markets, with CHC brands reaching consumers directly through retail channels. ECB drugs are supplied to healthcare institutions and pharmacies, while ESB products target specialized medical needs. Biosimilar collaborations with international partners enable the company to expand its portfolio beyond traditional pharmaceuticals, enhancing its market presence in both domestic and global segments. Duopharma Biotech Bhd's revenue streams are diversified across consumer-facing CHC products, generic ECB drugs, and specialized ESB solutions. The company leverages its established brands and partnerships to serve both mass-market and niche healthcare segments, ensuring steady demand for its pharmaceutical offerings in Malaysia and beyond. Duopharma Biotech Bhd is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Duopharma Biotech Bhd's EBIT

Duopharma Biotech Bhd's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Duopharma Biotech Bhd's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Duopharma Biotech Bhd's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Duopharma Biotech Bhd’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Duopharma Biotech Bhd stock

EBIT of Duopharma Biotech Bhd is 100.65 M MYR in 2024.

EBIT of Duopharma Biotech Bhd changed from 78.71 M MYR to 100.65 M MYR, representing a 27.87% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Duopharma Biotech Bhd since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's MYR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Duopharma Biotech Bhd historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Duopharma Biotech Bhd

All Key Metrics — Duopharma Biotech Bhd